Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.

Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.

Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.

Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.

A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.

Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.

Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.

Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.

Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.

Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.

Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.